title: Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis.
abstract: OBJECTIVE
  Several studies have reported that the application of rebamipide during the eradication of Helicobacter pylori can improve the eradication rate. However, the efficacy and safety are controversial. The present study systematically evaluated whether rebamipide improves the eradication rate of H. pylori by conducting a meta-analysis based on randomized controlled trials (RCTs).
  
  
  METHODS
  Literature searches were conducted in the following database: PubMed, the Cochrane Library, and the Igaku-chuo-zasshi database in Japan. A meta-analysis of all RCTs comparing rebamipide supplementation with non-rebamipide-containing therapy was performed.
  
  
  RESULTS
  We identified six randomized trials (611 patients). Pooled H. pylori eradication rates by per-protocol analysis were 73.3% and 61.4% for patients with or without rebamipide, respectively. The odds ratio was 1.74 (95% confidence interval. 1.19-2.53).
  
  
  CONCLUSIONS
  Supplementation with rebamipide might be effective in increasing the H. pylori eradication rates of proton-pump inhibitor-amoxicillin dual therapy.
authors.affiliation: Division of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Tokyo, Japan; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Nishizawa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nishizawa
authors.forename: Naohisa
authors.initials: N
authors.lastname: Yahagi
authors.forename: Takanori
authors.initials: T
authors.lastname: Kanai
authors.forename: Masahiko
authors.initials: M
authors.lastname: Takahashi
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Suzuki
mesh_terms: D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D016206:Databases, Bibliographic; D004359:Drug Therapy, Combination; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology*; D016481:Helicobacter Infections; D016480:Helicobacter pylori; D006801:Humans; D016017:Odds Ratio; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D054328:Proton Pump Inhibitors; D015363:Quinolones; D000658:Amoxicillin; C052785:rebamipide; D000409:Alanine
keywords: Helicobacter pylori; eradication; rebamipide